Insulet (PODD) Just Overtook the 20-Day Moving Average
Insulet: Rivals Are Building Patch Pumps, But Insulet Already Owns The Pharmacy Counter
Is Insulet (PODD) a Solid Growth Stock? 3 Reasons to Think "Yes"
For World Diabetes Day, Insulet Launches "Give Yourself the Freedom to" Campaign, Encouraging People with Diabetes to Prioritize Their Well-Being
Truist Securities Reiterates Hold on Insulet, Raises Price Target to $160
Barclays Maintains Equal-Weight on Insulet, Raises Price Target to $165
Insulet (PODD) Stock May Be 36% Undervalued Despite $1b Buyback
UBS Maintains Neutral on Insulet, Raises Price Target to $171
JP Morgan Maintains Neutral on Insulet, Raises Price Target to $170
Citigroup Maintains Neutral on Insulet, Raises Price Target to $170
Leerink Partners Maintains Market Perform on Insulet, Raises Price Target to $167
RBC Capital Maintains Outperform on Insulet, Raises Price Target to $180
Bernstein Maintains Outperform on Insulet, Raises Price Target to $200
Wells Fargo Maintains Equal-Weight on Insulet, Raises Price Target to $172
Insulet Stock What’s Changed After Earnings Beat
Insulet Corp (PODD) Q3 2026 Earnings Call Highlights: Revenue Up 19%, EPS Jumps 60% and $1 ...
What Insulet (PODD) Said on Its Q3 Earnings Call
Insulet Corporation Q3 2026 Earnings Call Summary
Insulet (PODD) Q3 2026 Earnings Call Transcript
Insulet CEO Sees Slower Growth in 2027, Expects Rivals to Chip Away at Omnipod's Market Share
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.